Hansa Biopharma Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Hansa Biopharma de 27.3% y 41.8% por año respectivamente. Se prevé que el BPA crezca en un 38.2% al año. Se espera que la rentabilidad financiera sea de -110.1% en 3 años.

Información clave

27.3%

Tasa de crecimiento de los beneficios

38.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	38.7%
Tasa de crecimiento de los ingresos	41.8%
Rentabilidad financiera futura	-110.1%
Cobertura de analistas	Low
Última actualización	19 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Feb 07

Recent updates

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Apr 05

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Feb 07

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Dec 28

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Oct 13

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Feb 06

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Feb 01

Previsiones de crecimiento de beneficios e ingresos

OM:HNSA - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	459	-797	-491	-470	3
12/31/2025	343	-712	-365	-347	4
12/31/2024	239	-735	-560	-548	3
3/31/2024	166	-845	-738	-738	N/A
12/31/2023	134	-832	-756	-756	N/A
9/30/2023	114	-856	-697	-693	N/A
6/30/2023	159	-759	-629	-626	N/A
3/31/2023	148	-678	-583	-579	N/A
12/31/2022	155	-611	-506	-503	N/A
9/30/2022	139	-626	-509	-509	N/A
6/30/2022	77	-620	-514	-514	N/A
3/31/2022	55	-583	-493	-491	N/A
12/31/2021	34	-548	-484	-481	N/A
9/30/2021	22	-491	-464	-461	N/A
6/30/2021	18	-465	-327	-325	N/A
3/31/2021	14	-431	-291	-290	N/A
12/31/2020	6	-421	-291	-290	N/A
9/30/2020	3	-426	-270	-269	N/A
6/30/2020	3	-398	-357	-354	N/A
3/31/2020	3	-381	-358	-354	N/A
12/31/2019	3	-360	-338	-335	N/A
9/30/2019	4	-330	-320	-317	N/A
6/30/2019	3	-298	-293	-291	N/A
3/31/2019	4	-274	-264	-262	N/A
12/31/2018	3	-248	-207	-205	N/A
9/30/2018	3	-216	-179	-176	N/A
6/30/2018	3	-192	-164	-161	N/A
3/31/2018	3	-178	-153	-150	N/A
12/31/2017	3	-177	N/A	-150	N/A
9/30/2017	3	-161	N/A	-148	N/A
6/30/2017	3	-151	N/A	-137	N/A
3/31/2017	3	-136	N/A	-121	N/A
12/31/2016	3	-111	N/A	-95	N/A
9/30/2016	4	-97	N/A	-83	N/A
6/30/2016	3	-84	N/A	-72	N/A
3/31/2016	3	-76	N/A	-67	N/A
12/31/2015	7	-66	N/A	-58	N/A
9/30/2015	5	-60	N/A	-50	N/A
6/30/2015	5	-51	N/A	-39	N/A
3/31/2015	4	-34	N/A	-29	N/A
12/31/2014	2	-29	N/A	-24	N/A
9/30/2014	2	-21	N/A	-19	N/A
6/30/2014	3	-20	N/A	-17	N/A
3/31/2014	3	-19	N/A	-14	N/A
12/31/2013	2	-18	N/A	-15	N/A
9/30/2013	2	-16	N/A	-14	N/A
6/30/2013	3	-15	N/A	-18	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que HNSA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que HNSA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que HNSA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (41.8% al año) de HNSA crezcan más rápidamente que los del mercado Swedish (1.5% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (41.8% al año) de HNSA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: HNSA se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Hansa Biopharma Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 7.0% to kr103

Consensus revenue estimates increase by 17%

Consensus revenue estimates decrease by 21%

Consensus revenue estimates decrease by 16%, EPS upgraded

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

No longer forecast to breakeven

Recent updates

Price target decreased by 7.0% to kr103

Consensus revenue estimates increase by 17%

New minor risk - Shareholder dilution

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Consensus revenue estimates decrease by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Hansa Biopharma AB (Publ) Announces CFO Changes

Consensus revenue estimates decrease by 16%, EPS upgraded

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Financial position

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Forecast to breakeven in 2026

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

President & CEO recently bought kr115k worth of stock

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Third quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Profitability

Consensus revenue estimates fall by 17%

Price target decreased by 12% to kr148

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

New minor risk - Share price stability

Consensus revenue estimates decrease by 33%

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Consensus EPS estimates fall by 11%, revenue upgraded

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 10%, revenue upgraded

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Price target decreased to kr176

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

Senior VP recently bought kr346k worth of stock